CAR-T cell Therapy Market is expected to reach US$ 10.13 billion by 2030

Publisher: The Insight Partners

CD19 Segment to Hold Significant Market Share of CAR-T Cell Therapy Market During 2022–2030  

According to our latest study on "CAR-T cell Therapy Market Forecast to 2030 – Global Analysis – Targeted Antigen, Indication, End User," the market is expected to reach US$ 10.13 billion by 2030 from US$ 2.79 billion in 2022. It is expected to record a CAGR of 17.5% during 2022–2030.

The report emphasizes the key factors driving the market and prominent players’ developments. Factors such as the growing adoption and use of CAR-T cell therapy and the increasing prevalence of cancer are contributing to the growing CAR-T cell therapy market size. However, the side effects of CAR-T cell therapy and challenges faced while commercializing the products restrict the CAR-T cell therapy market growth.  

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00029935

After years of dominance in the cell and gene therapy (C&GT) field, chimeric antigen receptor (CAR) T cells led to the approval and commercialization of Kymriah in 2017, the first therapy of its kind. The development of CAR-T cell therapy has transformed how some cancers are treated and is still a subject of active research and innovation. Since then, CAR-T therapies have been the subject of the most research worldwide, and five additional products, i.e., Yescarta, Abecma, Tecartus, Breyanzi, and Carvykti—based on this technology—have been approved for the treatment of various blood cancers.

Companies operating in the T cell therapy market focus on strategic developments such as collaborations, expansions, agreements, and investments. These help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. In January 2024, Regeneron Pharmaceuticals announced the formation of Regeneron Cell Medicines, a new R&D unit formed through an agreement with 2seventy bio, a US-based immune-oncology cell therapy company. Regeneron has acquired full development and commercialization rights to 2seventy bio’s pipeline of investigational novel immune cell therapies, as well as the company’s discovery and clinical manufacturing capabilities, under the terms of the agreement. The divestment allows 2seventy bio to concentrate solely on the commercialization and development of Abecma (idecabtagene vicleucel), a B cell maturation antigen (BCMA)-targeted CAR-T cell therapy for treating multiple myeloma.

In November 2023, Legend Biotech, a biotechnology company, signed an exclusive global license agreement with Novartis for certain Legend Biotech  CAR-T cell therapies that target Delta-like ligand protein 3 (DLL3). The deal includes Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102 (NCT05680922).

Innovations highlight the dynamic nature of CAR-T cell therapy research, focusing on improving these therapies’ safety, efficacy, and applicability across a broader spectrum of solid and hematologic cancers and introducing new CAR-T cell therapy market trends in the coming years.

CAR-T Cell Therapy Market, by Targeted Antigen:

Based on targeted antigen, the market is bifurcated into CD19 and BCMA. The CD19 segment held a larger CAR-T cell therapy market share in 2022 and is anticipated to register a higher CAGR of 17.9% during the forecast period. An innovative kind of immunotherapy called CD19 CAR-T cell therapy treats some blood cancers, mainly B-cell malignancies. A chimeric antigen receptor (CAR), intended to bind and recognize CD19, a protein present on the surface of B cells, including cancerous B cells, is expressed on T cells through genetic modification. Treatment for certain types of leukemia and lymphoma has shown remarkable success with CD19 CAR-T cell therapy. This treatment is a promising development in the fight against cancer.

CAR-T Cell Therapy Market, by Indication:

By indication, the market is segmented into lymphomas, leukemia, and multiple myeloma. The lymphomas indication segment held the largest CAR-T cell therapy market share in 2022 and is anticipated to register the highest CAGR of 18.1% during the forecast period. As CD19 is a protein expressed on the surface of B cells, it has a major role in hematologic malignancies like lymphoma, myeloma, and leukemia. CD19 has become a vital target for treatments like CAR-T cell therapy in treating cancer. In situations where conventional treatments might not be successful, CAR-T cell therapy has demonstrated remarkable success rates in treating some lymphoma and leukemia by targeting CD19. Despite the encouraging outcomes of CD19-targeted therapies, further investigation is needed to determine how to enhance and broaden their use in treating lymphomas, leukemia, and multiple myeloma.

CAR-T cell Therapy Market, by Geography:

The scope of the CAR-T cell therapy market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), and Rest of World. In the US, CAR-T cell therapy has earned laurels in keeping specific blood cancers at bay. Kymriah and Yescarta are the CAR-T cell therapies approved for treating specific types of leukemia and lymphoma. In ongoing clinical trials, CAR-T cell therapy is being investigated for various hematologic malignancies. The US is a center for this kind of research and development, with numerous institutions working to advance CAR-T cell therapy. US researchers are working to improve CAR-T cell therapies, find new targets besides CD19, and broaden the use of this treatment for other cancer types. Overall, CAR-T cell therapy has become a significant and promising part of the oncology landscape in the US, offering new hope for patients with specific hematologic malignancies.

Apart from factors driving the market, the CAR-T cell therapy market report emphasizes prominent players' developments. Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., CARsgenTherapeutics Co., Ltd, Aurora Biopharma, Legend Biotech, Pfizer Inc., bluebird bio, Inc., Mustang Bio, Sorrento Therapeutics, Inc., and Fate Therapeutics are among the prominent players in operating in the market.

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com